April 2022

NEWS & COLUMNS

6-7 NEWS
Novartis and Voyager in $1.7bn gene therapy deal; FDA approves Carvykti for multiple myeloma

8-9 NEWS
NICE recommends Amgen’s Lumykras for lung cancer; IMC outlines need to combat AMR

10-11 CORONAVIRUS NEWS
AstraZeneca’s Evusheld receives MHRA approval; FDA reviews need for COVID-19 booster shots

12 DARWIN'S MEDICINE
Why is it so hard to achieve excellence?

13 POLICY AND PUBLIC HEALTH
A zero-sum game, with winners and losers

14 FOLLOWING THE TREND
12 key healthcare trends from the HCA

15 PHARMA MARKETERS' BLOG
A comprehensive customer experience strategy

FEATURES

16-17 NOW THE FACE MASKS AND GLOVES ARE OFF – IT'S TIME TO TACKLE DISPUTES
For two years, life sciences firms have co-operated for the greater good, but is the tide beginning to turn and is a wave of litigation on the horizon? Catherine Penny explains the potential for new forms of litigation in life sciences disputes

22-23 CLINICAL TRIALS AND THE PATIENT'S PERSPECTIVE
The successful recruitment and retention of patients is a crucial part of delivering clinical studies, but in these eventful and high-pressured times for the pharmaceutical and clinical research sector, it can be all too easy to overlook how building relationships with patients and managing them appropriately is fundamental to delivering successful and efficient clinical trials.